There are 383 resources available
Invited Discussant of 80O and 141O
Presenter: Federico Cappuzzo
Session: Proffered Paper session
Resources:
Slides
Webcast
Q&A
Session: Proffered Paper session
Resources:
Webcast
Live Q&A
Presenter: Enriqueta Felip
Session: Janssen Pharmaceutica - Evolving treatment options and practices in EGFR-mutant NSCLC
Resources:
Webcast
Welcome and introductions
Presenter: Antonio Passaro
Session: Janssen Pharmaceutica - Evolving treatment options and practices in EGFR-mutant NSCLC
Resources:
Webcast
Discussion - Unmet needs in the management of EGFR+ NSCLC
Presenter: Benjamin Besse
Session: Janssen Pharmaceutica - Evolving treatment options and practices in EGFR-mutant NSCLC
Resources:
Webcast
Discussion - Advances in the treatment of patients with EGFR exon20ins+ NSCLC
Presenter: Anna Minchom
Session: Janssen Pharmaceutica - Evolving treatment options and practices in EGFR-mutant NSCLC
Resources:
Webcast
Introduction
Presenter: Marina Garassino
Session: ESMO Colloquium supported by Eli Lilly and Co. - One tumour, many faces: Optimising testing, targeting and monitoring oncogene-addicted NSCLC beyond EGFR
Resources:
Slides
Webcast
Tissue testing for actionable biomarkers in patients with advanced NSCLC: Scientific and implementation perspectives and the positioning of molecular tumour boards
Presenter: Fernando Lopez-Rios
Session: ESMO Colloquium supported by Eli Lilly and Co. - One tumour, many faces: Optimising testing, targeting and monitoring oncogene-addicted NSCLC beyond EGFR
Resources:
Slides
Webcast
An overview of molecular epidemiology of rare molecular aberrations and matching treatment strategies for patients with non-EGFR, oncogene-addicted advanced NSCLC
Presenter: Fabrice Barlesi
Session: ESMO Colloquium supported by Eli Lilly and Co. - One tumour, many faces: Optimising testing, targeting and monitoring oncogene-addicted NSCLC beyond EGFR
Resources:
Slides
Webcast
RET-fused NSCLC: State of the art treatment of advanced disease, including sanctuary sites
Presenter: Marina Garassino
Session: ESMO Colloquium supported by Eli Lilly and Co. - One tumour, many faces: Optimising testing, targeting and monitoring oncogene-addicted NSCLC beyond EGFR
Resources:
Slides
Webcast